Efaproxiral (sodium)

• Description :

  Efaproxiral sodium (RSR13 sodium) is a synthetic allosteric modifier of haemoglobin (Hb), decreases Hb-oxygen (O2) binding affinity and enhances oxygenation of hypoxic tumours during radiation therapy. in vitro: Efaproxiral increases oxygen levels in hypoxic tumor tissues by binding non-covalently to the hemoglobin tetramer and decreasing hemoglobin-oxygen binding affinity. Increasing tumor oxygenation reduces tumor radioresistance. Efaproxiral can enhance the oxygenation of hypoxic tumours and function as a radiation sensitiser, increasing the effectiveness of RT.

• Product Name Alternative :

  RSR13 (sodium)

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Reactive Oxygen Species (ROS)

• Type :

  Reference compound

• Related Pathways :

  Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Efaproxiral-sodium.html

• Purity :

  99.72

• Solubility :

  DMSO : 175 mg/mL (ultrasonic) |H2O : ≥ 33.33 mg/mL

• Smiles :

  CC(C)(OC1=CC=C(CC(NC2=CC(C)=CC(C)=C2)=O)C=C1)C(O[Na])=O

• Molecular Formula :

  C20H22NNaO4

• Molecular Weight :

  363.38

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Stea B, et al. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases. Br J Cancer. 2006 Jun 19;94 (12) :1777-1784.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [170787-99-2]